unknown
Stage
2
Investors
About
Achaogen develops antibiotic treatments, including ZEMDRI® (plazomicin), which is approved in the US for treating complicated urinary tract infections caused by certain multidrug-resistant Enterobacterales bacteria.
Explore Achaogen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.